Consolidated Statements of Stockholders Deficit - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2018	$ 15	$ 230,754	$ (219,461)	$ (2,909)	$ 5,760	$ 14,159
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Stock-based compensation	$ 0	340	0	0	$ 0	340
Series A Preferred Stock Dividends	0	0	(248)	0	0	(248)
Issuance of SYN Biomics Stock	$ 0	(36)	0	108	$ 0	72
Conversion of Series B Preferred Stock to Common (in shares)	1,324,347				(1,523)
Conversion of Series B Preferred Stock to Common	$ 2	1,522	(525)	0	$ (999)	0
Net loss	0	0	(15,303)	0	0	(15,303)
Non-controlling interest	0	0	0	(77)	0	(77)
Balance at Dec. 31, 2019	$ 17	232,580	(235,537)	(2,878)	$ 4,761	(1,057)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Stock-based compensation	$ 0	350	0	0	$ 0	350
Stock issued under "at-the-market" offering	$ 9	3,350	0	0	0	3,359
Stock issued under "at-the-market" offering (in shares)	9,256,535
Series A Preferred Stock Dividends	$ 0	0	(254)	0	0	(254)
Issuance of SYN Biomics Stock	0	0	0	178	0	178
Effect of Warrant exercise price adjustment	$ 0	880	(880)	0	$ 0	0
Conversion of Series B Preferred Stock to Common (in shares)	3,186,960				(3,665)
Conversion of Series B Preferred Stock to Common	$ 3	3,661	(1,380)	0	$ (2,284)	0
Net loss	0	0	(10,043)	0	0	(10,043)
Non-controlling interest	0	0	0	(73)	0	(73)
Balance at Dec. 31, 2020	$ 29	$ 240,821	$ (248,094)	$ (2,773)	$ 2,477	$ (7,540)
Balance (in shares) at Dec. 31, 2020	29,249,925				3,973